Insider Cluster (2 insiders) ·Filed Aug 5, 2026

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago
Insider cluster: 2 insiders, $1.3M total
Actionable Insight • Neutral

The insider sales are mechanically tied to option exercises and are trivial relative to Teva's $40.5B market cap. No bearish signal. Monitor the upcoming H2 ramp implied by maintained non-GAAP EPS guidance of $1.91-$2.11 and the Fitch upgrade to BBB- for the real earnings story.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
TEVA ▲ +5.16% at T+20d
NEUTRAL call ✓ call won +5.16% · α vs SPY +4.56% · entry $34.81 → $36.61
Next anchor: T+60d in 27d
Latest observation: T+39 +21.51% FF3 residual α
Entry anchored
Aug 5, 04:00 PM ET
via 1-min bar
T+1d
+1.58%
call +1.58% · α +0.97%
$35.36
settled 8w ago
T+5d
+4.70%
call +4.70% · α +3.49%
$36.45
settled 7w ago
T+20d
+5.16%
call +5.16% · α +4.56%
$36.61
settled 4w ago
T+60d
—
call — · α —
—
in 27d

Price Chart

Loading chart...

Executive Summary

Two Teva insiders (Hughes and Jover) sold a combined $1.34M in open-market shares on August 3, 2026, at ~$34.88/share, following the exercise of stock options at $0 exercise price. The sales occurred just 8 days after Teva's Q2 2026 earnings miss (revenue -1% YoY, GAAP loss of -$0.49/share), and represent 0.003% of Teva's $40.5B market cap — a trivial amount. The cluster is entirely option-exercise-and-sell transactions, a routine pattern for tax/cash purposes, not a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$1.3M
Insiders
2

Key Facts

  • Two insiders sold $1.34M total (0.003% of $40.5B market cap)
  • All sales were same-day option exercises at $0 exercise price — routine cash-out pattern
  • Sales occurred 8 days after Q2 earnings miss (revenue $4.14B, -1% YoY; GAAP EPS -$0.49)
  • No open-market purchases in the cluster — only derivative exercises followed by sales

Financial Impact

$1.34M in insider sales, representing 0.003% of market cap — immaterial

insider holdingsdilution

Risk Factors

  • Q2 revenue decline of -1% YoY and GAAP loss of -$0.49/share
  • $726M Emalex acquisition charge weighing on reported earnings
  • Insider cluster may be misread as bearish by less sophisticated traders

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TEVA-1786004921253
31 reports for TEVA
Performance horizon
100% Hit rate 9 of 9 directional calls best @ T+20▲ +17.61%Jul 20, 2026
Filters
Rows
Reports for TEVA — sortable, filterable
TypeNow
Sep 10, 2026
22d ago
Press Release
NEUTRAL ★ 5/10
$36.35 $39.19▲ +7.81%▲ +8.31%$39.29 (+8.09%)
Sep 8, 2026
24d ago
424B5
NEUTRAL ★ 5/10
$36.76 $39.25▲ +6.77%▲ +7.89%$39.29 (+6.88%)
Sep 2, 2026
4w ago
Court Ruling
NEUTRAL ★ 1/10
$37.49 $36.35▼ −3.04%▼ −2.08%$39.29 (+4.80%)
Aug 28, 2026
5w ago
Press Release
BULLISH ★ 6/10
$36.44 $36.36▼ −0.22%▼ −0.33%$39.29 (+7.82%)
Aug 25, 2026
5w ago
Court Ruling
NEUTRAL ★ 2/10
$38.10 $36.20▼ −4.99%▼ −4.46%$39.29 (+3.12%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$38.10 $36.20▼ −4.99%▼ −4.46%$39.29 (+3.12%)
Aug 10, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$36.14 $36.46▲ +0.89%▲ +0.93%$39.29 (+8.72%)
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$34.81 $36.45▲ +4.70%▲ +3.49%$39.29 (+12.87%)
Jul 31, 2026
9w ago
Court Ruling
BULLISH ★ 7/10
$35.01 $35.36▲ +1.00%▼ −2.51%$39.29 (+12.23%)
Jul 29, 2026
9w ago
8-K
MIXED ★ 5/10
$34.71 $34.72▲ +0.03%▼ −5.50%$39.29 (+13.20%)
Showing 10 of 31

US Market Status

Market Open — Closes in 3h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 6, 2026